|Dr. Edward M. Kaye||CEO & Director||668.37k||N/A||1949|
|Dr. Adrian R. Krainer Ph.D.||Co-Founder, Independent Director & Member of Scientific Advisory Board||119.5k||N/A||1959|
|Mr. Stephen J. Tulipano CPA, CPA, MBA||Chief Financial Officer||514.47k||N/A||1959|
|Ms. Isabel Aznarez Ph.D.||Co-Founder, VP & Head of Biology||N/A||N/A||1972|
|Dr. Huw M. Nash Ph.D.||COO & Chief Bus. Officer||N/A||N/A||1967|
|Ms. Joan Wood||Head of HR||N/A||N/A||N/A|
|Dr. Gene Liau||Exec. VP, Head of Research & Preclinical Devel.||N/A||N/A||1955|
|Dr. Barry S. Ticho FACC, M.D., Ph.D.||Chief Medical Officer||N/A||N/A||1960|
|Ms. Shamim Ruff||Sr. VP of Regulatory Affairs & Quality||N/A||N/A||1960|
|Ms. Nancy M. Wyant||VP & Head of Clinical Operations||N/A||N/A||1972|
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide medicines to treat the underlying causes of severe genetic diseases. Its lead product candidate, STK-001 used to treat Dravet syndrome, a severe and progressive genetic epilepsy. Stoke Therapeutics, Inc. has a partnership with Invitae Corporation to offer genetic testing. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was founded in 2014 and is headquartered in Bedford, Massachusetts.
Stoke Therapeutics, Inc.’s ISS Governance QualityScore as of January 22, 2021 is 10. The pillar scores are Audit: 2; Board: 10; Shareholder Rights: 7; Compensation: 9.